Research Papers: Pathology:
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
Metrics: HTML 670 views | ?
Antonio Viúdez1,2, Filipe L.F. Carvalho1, Zahra Maleki3, Marianna Zahurak4, Daniel Laheru1, Alejandro Stark1, Nilofer Z. Azad1, Christopher L. Wolfgang1, Stephen Baylin1, James G. Herman1, Ana De Jesus-Acosta1
1Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
2Department of Medical Oncology, Complejo Hospitalario de Navarra-Instituto de Investigaciones Sanitarias de Navarra-IDISNA, Pamplona, Navarra, Spain
3Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
4The Division of Biostatistics and Bioinformatics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Keywords: pancreatic neuroendocrine tumor, MGMT, NDRG-1, PHLDA-3, immunohistochemistry, Pathology Section
Received: October 01, 2015 Accepted: January 23, 2016 Published: February 17, 2016
Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.